Ausgabe 5/2023
Including Invited Reviews on Chemotherapy and renal dysfunction
Inhalt (13 Artikel)
Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii
Yoshihiko Maehara, Eiji Oki, Mitsuhiko Ota, Norifumi Harimoto, Koji Ando, Ryota Nakanishi, Tetsuro Kawazoe, Yoshiaki Fujimoto, Kentaro Nonaka, Hiroyuki Kitao, Makoto Iimori, Kunio Makino, Teiji Takechi, Takeshi Sagara, Kazutaka Miyadera, Kazuaki Matsuoka, Hiroshi Tsukihara, Yuki Kataoka, Takeshi Wakasa, Hiroaki Ochiiwa, Yoshihiro Kamahori, Eriko Tokunaga, Hiroshi Saeki, Tomoharu Yoshizumi, Yoshihiro Kakeji, Ken Shirabe, Hideo Baba, Mitsuo Shimada
Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists
Takeshi Matsubara, Hideki Yokoi, Hiroyuki Yamada, Motoko Yanagita
Anticancer drug therapy for patients with renal dysfunction
Koichi Suyama, Yuji Miura
Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center
Masashi Ando, Kazunori Honda, Waki Hosoda, Yuki Matsubara, Ryosuke Kumanishi, Taiko Nakazawa, Takatsugu Ogata, Akinobu Nakata, Hiroyuki Kodama, Toshiki Masuishi, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Kei Muro
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
Chikako Nakai, Sachiyo Mimaki, Koutatsu Matsushima, Eiji Shinozaki, Kentaro Yamazaki, Kei Muro, Kensei Yamaguchi, Tomohiro Nishina, Satoshi Yuki, Kohei Shitara, Hideaki Bando, Yutaka Suzuki, Kiwamu Akagi, Shogo Nomura, Satoshi Fujii, Masaya Sugiyama, Nao Nishida, Masashi Mizokami, Yasuhiro Koh, Takuya Koshizaka, Hideki Okada, Yukiko Abe, Atsushi Ohtsu, Takayuki Yoshino, Katsuya Tsuchihara
Impact of MIR31HG polymorphisms on risk of breast cancer in Chinese women
Ying Wei, Xiaolin Wang, Zhe Zhang, Changtao Zhao, Yuwei Chang, Zhiqing Bian, Xinhan Zhao
Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST
Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Yukinori Kurokawa, Kiyokazu Nakajima, Masahiro Koh, Takahiko Nishigaki, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Seiichi Hirota, Yoshito Hayashi, Tetsuo Takehara, Hidetoshi Eguchi, Yuichiro Doki
Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer
Hiroki Nakajima, Junpei Yamaguchi, Hideki Takami, Masamichi Hayashi, Yasuhiro Kodera, Yoshihiro Nishida, Nobuyuki Watanabe, Shunsuke Onoe, Takashi Mizuno, Yukihiro Yokoyama, Tomoki Ebata
Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy
Yu Imai, Fumihiko Urabe, Kosuke Iwatani, Minoru Nakazono, Kojiro Tashiro, Mariko Honda, Manabu Aoki, Shun Sato, Hiroyuki Takahashi, Kenta Miki, Takahiro Kimura
Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy
Takafumi Saito, Kazuhiro Matsumoto, Takeo Kosaka, Yota Yasumizu, Nobuyuki Tanaka, Toshikazu Takeda, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone
Ashita Ono, Takeshi Hashimoto, Toshihide Shishido, Yosuke Hirasawa, Naoya Satake, Kazunori Namiki, Kazuhiro Saito, Yoshio Ohno
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
Shunichi Sugawara, Masashi Kondo, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Koichi Goto, Kazuhiko Nakagawa, Takashi Seto, Nobuyuki Yamamoto, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Yuichiro Ohe
Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study
Renpei Kato, Sei Naito, Kazuyuki Numakura, Shingo Hatakeyama, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Shuya Kandori, Sadafumi Kawamura, Yoichi Arai, Akihiro Ito, Hiroyuki Nishiyama, Yoshiyuki Kojima, Chikara Ohyama, Tomonori Habuchi, Norihiko Tsuchiya, Wataru Obara